Copyright
©The Author(s) 2019.
World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Table 10 Assessment of liver fibrosis in individual studies
| Study | Parameter | Group | Baseline | Study completion | P value | P value between groups |
| Ito et al[12] | FIB-4 index | Ipragliflozin | 1.44 (0.64) | 1.22 (0.55) | < 0.05 | 0.596 |
| Pioglitazone | 1.84 (1.13) | 1.71 (1.19) | Non-significant | |||
| Ohki et al[15] | FIB-4 index | Ipragliflozin | 1.75 (0.82-1.93) | 1.39 (0.77-1.99) | 0.04 | - |
| Sumida et al[18] | FIB-4 index | Luseogliflozin | 1.63 (1.19) | 1.52 (0.92) | 0.17 | - |
| NAFLD fibrosis score | Luseogliflozin | 1.61 (0.71) | 1.62 (0.88) | 0.86 | - |
- Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
- URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114